| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,979 |
7,943 |
$698K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
14,795 |
10,762 |
$458K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,747 |
3,557 |
$92K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
747 |
545 |
$48K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
1,703 |
1,632 |
$15K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,431 |
10,312 |
$9K |
| 80053 |
Comprehensive metabolic panel |
11,187 |
10,237 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,825 |
1,680 |
$7K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,089 |
972 |
$6K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,183 |
953 |
$4K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
688 |
619 |
$4K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
549 |
496 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
14,909 |
13,355 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
573 |
533 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
409 |
367 |
$2K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
397 |
335 |
$2K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
28 |
27 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
460 |
415 |
$2K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
437 |
398 |
$1K |
| 81001 |
|
1,494 |
1,347 |
$884.33 |
| J2704 |
Injection, propofol, 10 mg |
823 |
342 |
$759.41 |
| 80061 |
Lipid panel |
2,102 |
2,013 |
$753.40 |
| 83690 |
|
478 |
428 |
$625.60 |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,794 |
1,717 |
$541.33 |
| 83605 |
|
283 |
260 |
$383.15 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
323 |
295 |
$368.08 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
245 |
106 |
$350.17 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
93 |
82 |
$333.15 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
260 |
228 |
$282.85 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
893 |
861 |
$246.50 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
520 |
467 |
$192.23 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
149 |
84 |
$158.78 |
| 84703 |
|
154 |
138 |
$139.27 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
163 |
157 |
$126.11 |
| 87070 |
|
379 |
363 |
$106.37 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
591 |
542 |
$89.35 |
| 96376 |
|
78 |
74 |
$84.87 |
| 87276 |
|
171 |
169 |
$83.43 |
| 87275 |
|
171 |
169 |
$83.37 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
59 |
53 |
$76.06 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
259 |
233 |
$69.03 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
14 |
12 |
$67.06 |
| 87088 |
|
218 |
202 |
$59.20 |
| 84484 |
|
312 |
282 |
$50.17 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
101 |
90 |
$49.95 |
| 87077 |
|
227 |
209 |
$46.03 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
246 |
218 |
$41.95 |
| 85610 |
|
188 |
133 |
$40.27 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
114 |
103 |
$33.72 |
| 87186 |
|
179 |
161 |
$32.30 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
190 |
184 |
$25.78 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
130 |
117 |
$20.28 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
111 |
99 |
$16.82 |
| 81025 |
|
105 |
98 |
$15.33 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
110 |
98 |
$13.24 |
| 85027 |
|
170 |
160 |
$9.47 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
129 |
117 |
$8.37 |
| 87205 |
|
45 |
42 |
$4.99 |
| 87147 |
|
48 |
45 |
$3.91 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
39 |
32 |
$2.70 |
| 82962 |
|
74 |
68 |
$2.00 |
| 85652 |
|
176 |
167 |
$1.89 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
329 |
132 |
$0.00 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
46 |
44 |
$0.00 |
| 86038 |
|
15 |
12 |
$0.00 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
142 |
63 |
$0.00 |
| 84439 |
|
143 |
133 |
$0.00 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
64 |
62 |
$0.00 |
| 73630 |
|
15 |
12 |
$0.00 |
| 82565 |
|
54 |
51 |
$0.00 |
| 84466 |
|
29 |
29 |
$0.00 |
| 83540 |
|
30 |
30 |
$0.00 |
| 71045 |
Radiologic examination, chest; single view |
26 |
25 |
$0.00 |
| 82728 |
|
46 |
46 |
$0.00 |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
113 |
43 |
$0.00 |
| 87430 |
|
62 |
55 |
$0.00 |
| 86140 |
|
132 |
122 |
$0.00 |
| 85379 |
|
50 |
49 |
$0.00 |
| 87081 |
|
101 |
96 |
$0.00 |
| 76830 |
Ultrasound, transvaginal |
45 |
43 |
$0.00 |
| 82043 |
|
63 |
63 |
$0.00 |
| 86803 |
|
46 |
41 |
$0.00 |
| 87807 |
|
29 |
29 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
35 |
30 |
$0.00 |
| G0475 |
Hiv antigen/antibody, combination assay, screening |
34 |
34 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
66 |
44 |
$0.00 |
| 82607 |
|
17 |
17 |
$0.00 |
| 82746 |
|
15 |
15 |
$0.00 |
| 83735 |
|
14 |
13 |
$0.00 |